SpaceX is without doubt one of the most exciting growth stocks to go public in years. But while there’s every chance that the rocket and satellite giant will grow into its valuation over time, I don’t think the fundamentals justify today’s $1.5trn market-cap.
Therefore, I reckon there are better opportunities than SpaceX right now. So here are three growth stocks I’ve recently bought for my portfolio I believe are worth a closer look.
Internet of Things
Kicking things off, we have Samsara (NYSE:IOT). This is an Internet of Things (IoT) company that helps businesses and organisations connect their real-world assets (delivery vans, trucks, trailers, construction equipment, etc) to its software platform.
With this real-time data, customers can cut fuel costs, improve driver behaviour, optimise maintenance schedules, detect pot holes, improve productivity and, ultimately, reduce insurance and operating costs.
I love businesses that offer a compelling customer proposition, and Samsara certainly ticks this box. It’s evolving from a telematics provider to an AI operating system for physical industries.
In Q1, revenue jumped 31% to $478.8m, with annual recurring revenue now topping $2bn. And that was its third consecutive quarter of being profitable, which de-risks the investment somewhat.
That said, there’s a lot of optimism baked into today’s valuation. It’s not SpaceX-level priciness, but a forward price-to-sales ratio of 10 means there’s no room for a slowdown in growth.
Down 36% since February 2025 though, I see Samsara as a dip-buying opportunity worth exploring further.
The long-term opportunity? To bring AI to the physical world, which represents 40% of global GDP.
Cashing in on the global health and fitness boom
My next pick is Applied Nutrition (LSE:APN) from the FTSE 250. This supplement and sports nutrition company is rapidly taking market share both in the UK and abroad.
In the six months to 31 January, sales surged 57% to £74.5m, while adjusted pre-tax profit rose 54% to £20.9m. Growth’s being driven by increasing shelf space with UK supermarkets and discounters, global expansion, and new product launches.
After jumping almost 150% in the past year, the stock isn’t conventionally cheap, at 24 times forward earnings. Similar to Samsara, this one could sell off if there’s an unexpected slowdown in sales growth.
The Middle East conflict also adds shipping disruption and inflationary pressures. But with an opportunity to take share in the massive but fragmented global sports nutrition market, I think the potential long-term rewards outweigh any near-term risks.
Our vision is to be the world’s most trusted and innovative sports nutrition, health and wellness brand.
Applied Nutrition
Buying the dip
Finally, I’m highlighting money transfer leader Wise (LSE:WISE), which I added to after a 17% dip since the start of May.
One setback was that Wise’s application to create a national trust bank in the US was rejected by regulators. While this could slow take-rate reductions and weigh on US customer growth, I don’t think it changes the long-term investment case.
That’s for Wise to become ‘the’ network for the world’s money. In Q1 FY27, cross-border volume increased 26% to $69.3bn, while customer holdings jumped 31% to $41.2bn. For the full year, Wise anticipates solid net revenue growth of 17%-18%.
After the recent stumble, this quality growth stock trades at a very-cheap-looking 18 times forward earnings.
Should you invest £5,000 in Wise Plc right now?
When investing expert Mark Rogers and his team have a stock tip, it can pay to listen. After all, the flagship Twelfth Magpie Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.
And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Wise Plc made the list?
Ben McPoland owns shares in Applied Nutrition, Samsara, and Wise.
